Select publications

Publications discussed by Dr Lawton

Critz FA et al. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 2000;163(4):1085-9. Abstract

Critz FA et al. Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: The relationship to patient age. J Urol 2003;170(5):1864-7. Abstract

Hanks GE et al. Phase III Trial of Long-Term Adjuvant Androgen Deprivation After Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21(21):3972-8. Abstract

Horwitz EM et al. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 2001;49(4):947-56. Abstract

Lawton CA et al. Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (Results based on a national prospective randomized trial, RTOG-85-31). Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1997;38(5):931-9. Abstract

Lawton CA et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49(4):947-56. Abstract

Pilepich MV et al. Androgen suppression adjuvant to radiotherapy in carcinoma of the prostate. Long-term results of phase III RTOG study 85-31. Int J Radiat Oncol Biol Phys 2003;57(2 Suppl):S172-3. No abstract available

Pilepich MV et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50(5):1243-52. Abstract

Pilepich MV et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997;15(3):1013-21. Abstract

Shipley WU et al. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: A secondary analysis of the randomized protocol RTOG 86-10. Int J Radiat Oncol Biol Phys 2002;54(5):1302-10. Abstract

Home

Editor’s Note:
The Waiting Room

Gregory S Merrick, MD
    - Select publications

Judd W Moul, MD, FACS
    - Select publications

Colleen A Lawton, MD, FACR
    - Select publications

Editor’s Office